Abvc Biopharma annual revenue
2010
2011
2012
2013
2014
2015
2015
2018
2019
2020
2021
2022
2023
2024
2025
Abvc Biopharma Revenue Growth & History (ABVC)
Abvc Biopharma reported $296,000 in revenue for fiscal 2025.
View full Abvc Biopharma company overviewAbvc Biopharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $296,000 | $296,000 | — |
| 2024 | 2024-12-31 | $0 | −$152,430 | −100.00% |
| 2023 | 2023-12-31 | $152,430 | −$817,353 | −84.28% |
| 2022 | 2022-12-31 | $969,783 | $613,986 | +172.57% |
| 2021 | 2021-12-31 | $355,797 | −$127,248 | −26.34% |
| 2020 | 2020-12-31 | $483,045 | −$218,674 | −31.16% |
| 2019 | 2019-12-31 | $701,719 | $694,763 | +9987.97% |
| 2018 | 2018-12-31 | $6,956 | — | — |
| 2015 · Dec 31 | 2015-12-31 | $50.0M | — | — |
| 2015 · Sep 30 | 2015-09-30 | $3,360 | $3,360 | — |
| 2014 | 2014-09-30 | $0 | −$7,787 | −100.00% |
| 2013 | 2013-09-30 | $7,787 | $2,073 | +36.28% |
| 2012 | 2012-09-30 | $5,714 | $2,524 | +79.12% |
| 2011 | 2011-09-30 | $3,190 | −$11,670 | −78.53% |
| 2010 | 2010-09-30 | $14,860 | — | — |
Abvc Biopharma quarterly revenue
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.17
Q3.17
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | −$795,950 | −$288,327 | −56.80% |
| Q3 2025 | 2025-09-30 | $795,950 | $406,674 | +104.47% |
| Q2 2025 | 2025-06-30 | $0 | −$117,142 | −100.00% |
| Q1 2025 | 2025-03-31 | $0 | −$1,205 | −100.00% |
| Q4 2024 | 2024-12-31 | −$507,623 | −$509,788 | −23546.79% |
| Q3 2024 | 2024-09-30 | $389,276 | $373,392 | +2350.74% |
| Q2 2024 | 2024-06-30 | $117,142 | $111,033 | +1817.53% |
| Q1 2024 | 2024-03-31 | $1,205 | −$127,067 | −99.06% |
| Q4 2023 | 2023-12-31 | $2,165 | −$586,829 | −99.63% |
| Q3 2023 | 2023-09-30 | $15,884 | −$26,385 | −62.42% |
| Q2 2023 | 2023-06-30 | $6,109 | −$306,751 | −98.05% |
| Q1 2023 | 2023-03-31 | $128,272 | $102,612 | +399.89% |
| Q4 2022 | 2022-12-31 | $588,994 | $626,787 | +1658.47% |
| Q3 2022 | 2022-09-30 | $42,269 | −$56,730 | −57.30% |
| Q2 2022 | 2022-06-30 | $312,860 | $281,419 | +895.07% |
| Q1 2022 | 2022-03-31 | $25,660 | −$237,490 | −90.25% |
| Q4 2021 | 2021-12-31 | −$37,793 | −$99,986 | −160.77% |
| Q3 2021 | 2021-09-30 | $98,999 | −$16,554 | −14.33% |
| Q2 2021 | 2021-06-30 | $31,441 | −$195,072 | −86.12% |
| Q1 2021 | 2021-03-31 | $263,150 | $184,364 | +234.01% |
| Q4 2020 | 2020-12-31 | $62,193 | −$37,769 | −37.78% |
| Q3 2020 | 2020-09-30 | $115,553 | −$82,180 | −41.56% |
| Q2 2020 | 2020-06-30 | $226,513 | $34,731 | +18.11% |
| Q1 2020 | 2020-03-31 | $78,786 | −$133,456 | −62.88% |
| Q4 2019 | 2019-12-31 | $99,962 | — | — |
| Q3 2019 | 2019-09-30 | $197,733 | $196,986 | +26370.28% |
| Q2 2019 | 2019-06-30 | $191,782 | $188,553 | +5839.36% |
| Q1 2019 | 2019-03-31 | $212,242 | — | — |
| Q3 2018 | 2018-09-30 | $747 | — | — |
| Q2 2018 | 2018-06-30 | $3,229 | −$86,771 | −96.41% |
| Q3 2017 | 2017-06-30 | $90,000 | — | — |
| Q1 2017 | 2016-12-31 | $70,000 | — | — |
| Q4 2015 | 2015-09-30 | $1,100 | $1,100 | — |
| Q3 2015 | 2015-06-30 | $0 | $0 | — |
| Q2 2015 | 2015-03-31 | $2,260 | $2,260 | — |
| Q1 2015 | 2014-12-31 | $0 | $0 | — |
| Q4 2014 | 2014-09-30 | $0 | $0 | — |
| Q3 2014 | 2014-06-30 | $0 | $0 | — |
| Q2 2014 | 2014-03-31 | $0 | −$761 | −100.00% |
| Q1 2014 | 2013-12-31 | $0 | −$7,026 | −100.00% |
| Q4 2013 | 2013-09-30 | $0 | $0 | — |
| Q3 2013 | 2013-06-30 | $0 | $0 | — |
| Q2 2013 | 2013-03-31 | $761 | −$2,904 | −79.24% |
| Q1 2013 | 2012-12-31 | $7,026 | $4,977 | +242.90% |
| Q4 2012 | 2012-09-30 | $0 | $0 | — |
| Q3 2012 | 2012-06-30 | $0 | $0 | — |
| Q2 2012 | 2012-03-31 | $3,665 | $2,945 | +409.03% |
| Q1 2012 | 2011-12-31 | $2,049 | −$421 | −17.04% |
| Q4 2011 | 2011-09-30 | $0 | — | — |
| Q3 2011 | 2011-06-30 | $0 | −$2,829 | −100.00% |
| Q2 2011 | 2011-03-31 | $720 | — | — |
| Q1 2011 | 2010-12-31 | $2,470 | — | — |
| Q3 2010 | 2010-06-30 | $2,829 | — | — |
Abvc Biopharma revenue growth trends
Over the last five reported fiscal years, revenue declined from $483,045 to $296,000, a compound annual decline of 9.33%. Abvc Biopharma's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Abvc Biopharma source filings ↗